Issues related to targeted delivery of proteins and peptides
- 1 September 2006
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 8 (3) , E466-E478
Abstract
While modern genomic and proteomic technology enables rapid screening of novel proteins and peptides as potential drug candidates, design of delivery systems for these biologics remains challenging especially to achieve site-specific pharmacological actions. This article discusses the issues associated with targeted delivery of protein and peptide drugs at physiochemical, physiological, and intracellular levels with a special focus on cancer therapy.Keywords
This publication has 112 references indexed in Scilit:
- The immunocytokine scFv23/TNF sensitizes HER-2/neu–overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1Molecular Cancer Therapeutics, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Use of multiple biomarkers for a molecular diagnosis of prostate cancerInternational Journal of Cancer, 2004
- Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdvanced Drug Delivery Reviews, 2003
- Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptorsThe Prostate, 2003
- Molecular regulation of vessel maturationNature Medicine, 2003
- Specialization of tumour vasculatureNature Reviews Cancer, 2002
- Interactions of antimitotic peptides and depsipeptides with tubulinPeptide Science, 2002
- TARGETED LIPOSOMES FOR DELIVERY OF PROTEIN-BASED DRUGS INTO THE CYTOPLASM OF TUMOR CELLSJournal of Liposome Research, 2002
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982